EUCTR2005-006060-63-DE进行中（未招募）不适用
A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia - fenofibrate and metformin fixed combination vs rosiglitazone
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 690
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At inclusion (V0):
- •1. Male or female aged from 18 to 75 years old,
- •2. With type 2 diabetes mellitus and dyslipidemia inadequately controlled with lifestyle modifications (diet and exercise),
- •3. With antidiabetic drug status as follows:
- •Antidiabetic drug naive patients: who have never been on prior antidiabetic drug treatment,
- •Antidiabetic drug free patients: who have not received antidiabetic drug treatment in the last 6 months,
- •4. Having signed a written informed consent.
- •At randomization (V1):
- •5. FPG = 126 mg/dL dL (= 7.0 mmol/L) and < 300 mg/dL (< 16.7 mmol/L). Glycemic status of the patients will be confirmed based on two FPG assays, BV0 and BV1,
- •6. HbA1c = 6.5% and = 9.5%,
- •7. Hypertriglyceridemia with or without hypercholesterolemia, defined by TG = 150 mg/dL and = 400 mg/dL (TG = 1.69 mmol/L and = 4.52 mmol/L), assayed at BV1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient with any of the following conditions will not be included in the trial:
- •1. Known Type 1 diabetes,
- •2. With LDL-C > 130mg/dL (3.35 mmol/L),
- •3. In cardiovascular secondary prevention,
- •4. Body mass index > 40 kg/m2,
- •5. Women who are not postmenopausal if they are not surgically sterilized (i.e. bilateral tubal ligation, bilateral or two unilateral oophorectomies, hysterectomy), or not using highly effective contraceptive precautions (i.e. oral contraceptives, approved hormonal implant, intrauterine device)
- •6. Pregnant or lactating women,
- •7. Known hypersensitivity to fibrates, metformin, rosiglitazone or any of their components or known photoallergic or phototoxic reactions under treatment with fibrates or ketoprofen,
- •8. Known allergy to peanut or arachis oil or soya lecithin or related products due to the risk of hypersensitivity reactions,
- •9. Having received an investigational drug in the last 30 days before date of inclusion,
- •10. Unable or unwilling to comply with the protocol and the standard diet and exercise recommendations,
- •11. Likely to withdraw from the study before its completion.
- •Concomitant medications:
- •12. Treated within the last 6 months before randomization with any antidiabetic drug treatment,
- •13. Treated within the last 2 months before randomization with a lipid-lowering drug (except statins). Patients who were on a statin before inclusion may be included provided the dose does not exceed the maximum daily dose authorized in the study (see Appendix 2) and is kept constant throughout the study.
- •14. Treated within the last 2 months before randomization with oral anticoagulants, with cyclosporin A, and any other immunosuppressive agent, with protease inhibitors (indinavir, ritonavir, saquinavir, …), for obesity by medical treatment (orlistat, sibutramine…) and/or surgery (gastroplasty, bypass,…), with rifampin (inducer of CYP2C8)
- •15. Change within the last 2 months before randomization, and during the course of the study, in the medications that could interfere with the lipid or glycemic profile.
- •Associated diseases or conditions:
- •16. Diabetic ketoacidosis, diabetic pre-coma,
- •17. Current chronic pancreatitis, or identified risk or known history of acute pancreatitis,
- •18. Known cholelithiasis without cholecystectomy,
- •19. Significant hepatic disease: AST and/or ALT > 2 times the upper limit of normal (ULN),
- •20. Musculoskeletal disease with increased creatine phosphokinase (CPK) > 3 times ULN,
- •21. Renal failure or renal dysfunction defined by a creatinine clearance < 60 mL/min as calculated with the Cockroft-Gault algorithm: creatinine clearance = [(140 - age) x weight (kg) / 7.2 x serum creatinine (mg/L)] for males and [x 0.85] in females,
- •22. Acute conditions with the potential to alter renal function (such as dehydration, severe infection, shock, intravascular administration of iodinated contrast agents),
- •23. Acute or chronic disease which may cause tissue hypoxia such as respiratory failure,
- •24. Known congestive heart failure or past medical history of congestive heart failure (class I to IV),
- •25. Known abnormal thyroid hormone levels, or high thyroid stimulating hormone (TSH) level. (clinically euthyroid subjects on stable replacement doses of thyroid hormone are eligible for inclusion),
- •26. Other uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins,
- •27. Patients particularly susceptible to hypoglycemic effects, such as debilitated, or malnourished patients, acute alcohol into
研究者
相似试验
进行中（未招募）
不适用
A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia - fenofibrate and metformin fixed combination vs rosiglitazonePatients with type 2 diabetes mellitus and dyslipidemiaMedDRA version: 8.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2005-006060-63-FIFOURNIER Laboratories Ireland Ltd690
已完成
3 期
A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemiadiabetes mellitus type 2 and dyslipidaemia10012653NL-OMON30160Fournier Laboratories72
进行中（未招募）
1 期
A randomized, double-blind trial comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia - fenofibrate and metformin fixed combination vs rosiglitazoneEUCTR2005-006060-63-NLFOURNIER Laboratories Ireland Ltd690
进行中（未招募）
不适用
A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin. - fenofibrate and metformin fixed combination vs metformiEUCTR2006-000924-15-CZFOURNIER Laboratories Ireland Ltd480
进行中（未招募）
不适用
A randomized, double-blind study comparing the efficacy and safety of a fixed combination of fenofibrate and metformin vs metformin alone in patients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statin - fenofibrate and metformin fixed combination vs metformiPatients with type 2 diabetes mellitus and dyslipidemia not appropriately controlled with a statinEUCTR2006-000924-15-HUFOURNIER Laboratories Ireland Ltd480